Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 44 716 6766461

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

BloomBoom Sep. 20 at 2:25 PM

$HELP Zero washout w/ a max 2hr treatment window vs 6 in cmps & required togo cold turkey off old meds. half the market cap of $CMPS and up only 100% ytd vs cmps @200% ytd. only a wouldn’t know how to play this one.

3 · Reply

PsychedelicBull Sep. 20 at 1:53 PM

$CMPS

0 · Reply

VikaDelic Sep. 20 at 11:08 AM

$CMPS ‘washout’ for non-clinical people. If two drugs are known or suspected to interact, you do a washout. It’s super uncommon- most antidepressants don’t even interact, we overlap + cross taper and it’s done differently between psychiatrists. Exception would be rarely used older antidepressants (MAOI’s) which legit interact w newer ones and require washout. Here’s the FUD false premise- clinical trial designs… of course we want to know exactly what a single drug is doing, so most clinical trials require a very simple semi restricted regimen of similar acting compounds or will do washout if there isn’t much data. Who is actually suggesting that you would arbitrarily stop all a severely depressed patient’s meds (washout) just to give them a compound that has shown no ability to interact with other antidepressants, which is already being testing in combination with various antidepressants (adjunct!). Dumb… and clinically irrelevant to how big the market will be regardless

1 · Reply

Skidit100 Sep. 20 at 2:37 AM

$CMPS Compass Pathways specifically conducted clinical trials evaluating COMP360 co-administered alongside ongoing selective SSRI regimens. The results demonstrated that COMP360 was generally well-tolerated and retained its antidepressant efficacy even when taken concurrently with SSRIs. If the FDA approves COMP360 for concurrent SSRI use washout will not be mandatory for standard SSRIs. Hope this clears things up

0 · Reply

RuddyRolls Sep. 20 at 2:34 AM

$CMPS $HELP @Millionaire11 @putINwork Thanks Brad, Emily, Alan Watts, Edward De Bono, Terence McKenna & The Mushroom! "The western mind is highly trained in rational, dualistic thinking, a lineage that traces itself all the way back to the ancient Greeks. Dualistic thinking is about comparison, differentiation, and splitting apart; in essence, it views the world as either this or that. It is an extremely important quality—one that underlies modern science and all the awesome, life-enhancing discoveries it has bequeathed us. But dualistic thinking is not the way only way to make sense of the world. And when it is applied to everything, we tend to run into problems. Some things in life truly are either-or, but many are both-and. Ancient wisdom traditions such as Buddhism and Taoism understand and teach the paradoxical nature of reality. They develop a non-dual mind." https://thegrowtheq.com/a-new-way-of-thinking-not-either-or-both-and/ https://www.carrienassifphd.com/blog/bothand

2 · Reply

Dazza933 Sep. 20 at 2:01 AM

$CMPS missing the enjoyment of markets being open, muscle memory to check stocktwits on the weekend for no key news 😂

1 · Reply

JensenNVDA Sep. 20 at 1:02 AM

@Millionaire11 @putINwork So what indications will HELP’s Deuterated Psilocybin be used for? This is great news that $CMPS has no competitors for TRD.

2 · Reply

abishop717 Sep. 20 at 12:32 AM

Still holding $BOOT $EPD $SDGR $CMPS

0 · Reply

JusaVaan Sep. 19 at 9:55 PM

$CMPS $HELP I believe you are wrong about $HELP 2-hour clinic time. $ATAI 5-meo-dmt has a 2 hours clinic time. I believe $HELP has said it could be about 4 hours.

1 · Reply

Millionaire11 Sep. 19 at 7:52 PM

$CMPS I’m sorry for getting argumentative. I want everybody to make money. I just like sharing my DD. I believe $HELP will do just fine. $CMPS is my bet and to me it is the obvious choice and i like to share my logic. I could be very wrong. In the end of the day our silly debates on stocktwits will not move the stock price. I wish everybody the best and good luck @putINwork I think you will do just fine in $HELP let’s win together.

2 · Reply

COMPASS Pathways Transcript: Deutsche Bank 2026 Healthcare Summit

Sep 16, 2026, 11:30 AM EDT - 4 days ago

COMPASS Pathways Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 16, 2026, 6:30 AM EDT - 4 days ago

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

Sep 15, 2026, 3:30 PM EDT - 4 days ago

COMPASS Pathways Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 15, 2026, 6:30 AM EDT - 5 days ago

Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

2026-09-11T20:15:10.000Z - 8 days ago

Strata Mental Health Solutions awarded training grant by Compass Pathways

Sep 11, 2026, 4:10 PM EDT - 8 days ago

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Sep 10, 2026, 8:00 AM EDT - 10 days ago

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Sep 10, 2026, 6:35 AM EDT - 10 days ago

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Sep 10, 2026, 6:30 AM EDT - 10 days ago

Compass Pathways to Participate in Investor Conferences the Week of September 14th

Sep 9, 2026, 4:40 PM EDT - 10 days ago

Compass Pathways Forecast: Breakout Could Target $22.51–$25.51

Sep 9, 2026, 3:20 PM EDT - 10 days ago

COMPASS Pathways Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

2026-09-09T10:35:53.000Z - 11 days ago

Compass Pathways reports 52-week results from Phase 3 COMP005 trial

Sep 9, 2026, 6:30 AM EDT - 11 days ago

Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Sep 8, 2026, 6:30 AM EDT - 12 days ago

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Sep 3, 2026, 4:30 PM EDT - 16 days ago

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2026, 6:30 AM EDT - 18 days ago

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

Sep 1, 2026, 6:30 AM EDT - 19 days ago

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

Aug 12, 2026, 8:00 AM EDT - 5 weeks ago

COMPASS Pathways Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-07T10:10:38.000Z - 6 weeks ago

Compass Pathways price target lowered to $65 from $70 at H.C. Wainwright

2026-08-06T15:50:56.000Z - 6 weeks ago

Compass Pathways price target raised to $18 from $17 at Morgan Stanley

2026-08-06T14:26:07.000Z - 6 weeks ago

Psychedelic: Compass Pathways, GH Research report quarterly earnings

CMND ENVB GHRS HELP

2026-08-06T13:38:16.000Z - 6 weeks ago

Compass Pathways price target raised to $22 from $17 at B. Riley

Aug 6, 2026, 7:00 AM EDT - 6 weeks ago

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

2026-08-06T10:54:31.000Z - 6 weeks ago

Compass Pathways price target lowered to $21 from $22 at RBC Capital

Aug 6, 2026, 6:30 AM EDT - 6 weeks ago

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

2026-08-05T20:11:44.000Z - 6 weeks ago

Compass Pathways files automatic mixed securities shelf

Aug 5, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Quarterly report: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Slides: Q2 2026

2026-08-05T10:46:59.000Z - 6 weeks ago

Compass Pathways reports Q2 EPS ($1.88), consensus (34c)

2026-08-05T10:46:08.000Z - 6 weeks ago

Compass Pathways current cash position sufficient throughout 2028

Aug 5, 2026, 6:30 AM EDT - 6 weeks ago

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Jul 29, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

2026-07-27T09:25:06.000Z - 7 weeks ago

Compass Pathways initiated with an Equal Weight at Wells Fargo

2026-07-17T18:15:10.000Z - 2 months ago

COMPASS Pathways PLC put volume heavy and directionally bearish

2026-07-16T10:40:21.000Z - 2 months ago

Compass Pathways’ COMP360 treatment featured in published PTSD trial

Jul 16, 2026, 6:35 AM EDT - 2 months ago

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

Jul 7, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Transcript: Study result

Jul 7, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Press release: Study result

Jul 7, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Slides: Study result

Jul 7, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Jul 6, 2026, 7:00 AM EDT - 2 months ago

COMPASS Pathways Slides: Investor presentation

Jun 26, 2026, 9:30 AM EDT - 2 months ago

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

DFTX

Jun 1, 2026, 10:00 AM EDT - 3 months ago

Why Trump Is Pushing Psychedelics To Treat Mental Illness

May 31, 2026, 8:00 AM EDT - 3 months ago

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare

May 28, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways Elects Kathleen Tregoning to Board of Directors

May 26, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

May 19, 2026, 10:00 AM EDT - 4 months ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 6:30 AM EDT - 4 months ago

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

COMPASS Pathways Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

COMPASS Pathways Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

COMPASS Pathways Slides: Investor presentation

May 13, 2026, 6:30 AM EDT - 4 months ago

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

May 6, 2026, 6:30 AM EDT - 4 months ago

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

Apr 27, 2026, 11:00 AM EDT - 4 months ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

Apr 24, 2026, 10:37 AM EDT - 4 months ago

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Apr 21, 2026, 6:30 AM EDT - 5 months ago

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026, 2:05 PM EDT - 5 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 5 months ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI DFTX GHRS

Apr 20, 2026, 8:26 AM EDT - 5 months ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 5 months ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 5 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI DFTX ENVB GHRS HELP

Apr 20, 2026, 6:30 AM EDT - 5 months ago

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Apr 18, 2026, 4:12 PM EDT - 5 months ago

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 15, 2026, 8:00 AM EDT - 5 months ago

COMPASS Pathways Proxy statement: Proxy filing

Apr 14, 2026, 12:45 PM EDT - 5 months ago

COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:30 AM EDT - 5 months ago

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026, 6:30 AM EDT - 5 months ago

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Mar 24, 2026, 7:30 AM EDT - 6 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 24, 2026, 7:00 AM EDT - 6 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 6 months ago

COMPASS Pathways Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 6 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 18, 2026, 10:30 AM EDT - 6 months ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 6:30 AM EDT - 6 months ago

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Mar 3, 2026, 10:30 AM EST - 6 months ago

COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:30 AM EST - 6 months ago

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Feb 24, 2026, 6:39 AM EST - 6 months ago

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Feb 18, 2026, 8:18 PM EST - 7 months ago

Compass Pathways Announces Pricing of $150 Million Public Offering

Feb 17, 2026, 4:06 PM EST - 7 months ago

Compass Pathways Launches Proposed $150.0 Million Public Offering

Feb 17, 2026, 8:00 AM EST - 7 months ago

COMPASS Pathways Transcript: Study update

Feb 17, 2026, 8:00 AM EST - 7 months ago

COMPASS Pathways Press release: Study update

Feb 17, 2026, 8:00 AM EST - 7 months ago

COMPASS Pathways Slides: Study update

Feb 17, 2026, 6:42 AM EST - 7 months ago

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17, 2026, 6:30 AM EST - 7 months ago

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Feb 16, 2026, 8:00 AM EST - 7 months ago

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Feb 9, 2026, 5:01 PM EST - 7 months ago

COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure

Jan 7, 2026, 10:00 AM EST - 8 months ago

COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 10:00 AM EST - 8 months ago

COMPASS Pathways Press release: KOL Event

Jan 7, 2026, 10:00 AM EST - 8 months ago

COMPASS Pathways Slides: KOL Event

Jan 7, 2026, 7:00 AM EST - 8 months ago

COMPASS Pathways Slides: Investor Presentation

Jan 7, 2026, 6:30 AM EST - 8 months ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 8 months ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

BloomBoom Sep. 20 at 2:25 PM

3 · Reply

PsychedelicBull Sep. 20 at 1:53 PM

$CMPS

0 · Reply

VikaDelic Sep. 20 at 11:08 AM

1 · Reply

Skidit100 Sep. 20 at 2:37 AM

0 · Reply

RuddyRolls Sep. 20 at 2:34 AM

2 · Reply

Dazza933 Sep. 20 at 2:01 AM

$CMPS missing the enjoyment of markets being open, muscle memory to check stocktwits on the weekend for no key news 😂

1 · Reply

JensenNVDA Sep. 20 at 1:02 AM

@Millionaire11 @putINwork So what indications will HELP’s Deuterated Psilocybin be used for? This is great news that $CMPS has no competitors for TRD.

2 · Reply

abishop717 Sep. 20 at 12:32 AM

Still holding $BOOT $EPD $SDGR $CMPS

0 · Reply

JusaVaan Sep. 19 at 9:55 PM

$CMPS $HELP I believe you are wrong about $HELP 2-hour clinic time. $ATAI 5-meo-dmt has a 2 hours clinic time. I believe $HELP has said it could be about 4 hours.

1 · Reply

Millionaire11 Sep. 19 at 7:52 PM

2 · Reply

Millionaire11 Sep. 19 at 7:38 PM

$CMPS $HELP I posted an article from their trial. Here ill post it again. https://ir.compasspathways.com/News--Events-/news/news-details/2021/COMPASS-Pathways-announces-positive-outcome-of-25mg-COMP360-psilocybin-therapy-as-adjunct-to-SSRI-antidepressants-in-open-label-treatment-resistant-depression-study/default.aspx?utm_source=chatgpt.com

1 · Reply

putINwork Sep. 19 at 7:37 PM

$CMPS $HELP once again I’m not looking at fireside chats or their website - I’m looking at TRIAL DESIGN AND ENROLLMENT WHICH THE FDA BASIS DRUG DOSING AND IMPLEMENTATION ON!!! HELP has no need for washout and is kinetically more stable - why would you want a 6 hr clinic time versus a 2 hr clinic time?!!!!!! EVEN IF CMPS could be tried with antidepressants why on earth would you prefer a 6hr clinic time?!! 🤣🤣🤣🤣 versus a 2 hour time?!!! Read the design of the trials themselves, that’s all I’m going to say. Yes, you do need to undergo a washout period and stop taking your current antidepressant to participate in standard trials for Compass Pathways' (CMPS) psilocybin treatment (COMP360).Unlike Cybin’s add-on approach, Compass Pathways has historically designed its pivotal clinical trials—including its major COMP005 and COMP006 Phase 3 trials for Treatment-Resistant Depression (TRD)—around the use of COMP360 as a monotherapy.

3 · Reply

Millionaire11 Sep. 19 at 7:32 PM

$CMPS $HELP “Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial All patients tolerated COMP360 psilocybin therapy well“ reading must be hard. https://ir.compasspathways.com/News--Events-/news/news-details/2021/COMPASS-Pathways-announces-positive-outcome-of-25mg-COMP360-psilocybin-therapy-as-adjunct-to-SSRI-antidepressants-in-open-label-treatment-resistant-depression-study/default.aspx?utm_source=chatgpt.com

0 · Reply

putINwork Sep. 19 at 7:31 PM

$CMPS $HELP Stop misleading people!!! HELP you can stay on your antidepressant and clinic times are shorter. CMPS you need to fully wash out which many patients won’t do. Yes, you do need to undergo a washout period and stop taking your current antidepressant to participate in standard trials for Compass Pathways' (CMPS) psilocybin treatment (COMP360).Unlike Cybin’s add-on approach, Compass Pathways has historically designed its pivotal clinical trials—including its major COMP005 and COMP006 Phase 3 trials for Treatment-Resistant Depression (TRD)—around the use of COMP360 as a monotherapy.Why Compass Pathways Requires a WashoutPreventing Drug Interactions: Traditional antidepressants (like SSRIs or SNRIs) alter serotonin receptors in the brain. Because psilocybin also targets these exact same receptors, being on an antidepressant can significantly blunt or completely block the therapeutic effects of the psychedelic.

3 · Reply

Millionaire11 Sep. 19 at 7:29 PM

$CMPS $HELP read https://ir.compasspathways.com/News--Events-/news/news-details/2021/COMPASS-Pathways-announces-positive-outcome-of-25mg-COMP360-psilocybin-therapy-as-adjunct-to-SSRI-antidepressants-in-open-label-treatment-resistant-depression-study/default.aspx?utm_source=chatgpt.com

0 · Reply

putINwork Sep. 19 at 7:27 PM

$CMPS $HELP Well did you even read the trial design of of CMPS?! Seems like you are wrong. Patients need a complete washout before starting and approval mimics what was studied in the trial not some speculative chat you mention

0 · Reply

Millionaire11 Sep. 19 at 7:26 PM

$CMPS $HELP @putINwork man can you read. There is no need to stop your antidepressants with COMP360 either in fact it is proven to work with and with out antidepressants. HELP only is proven to work with. There is an obvious difference in which is the better study.

0 · Reply

putINwork Sep. 19 at 7:23 PM

$CMPS $HELP What would I invest in??? The drug that’s going to be much much more practical for use in Psychiatry which is HELP = SHORTER CLINIC TIMES 2hrs vs 6 due to deuterated psilocybin and NO NEED TO STOP YOUR ANTIDEPRESSANT- AND NO MEDS CURRENTLY SPECIFICALLY FOR TREATMENT RESISTANT DEPRESSION which is highly prevalent. I’m bullish on both but in the near term HELP has phase 3 data that is based on FDA breakthrough designation. It also has a much more KINETICALLY STABLE deuterated psilocybin (meaning clinic times are 2 hours not 6 which is huge for patient care). HELP is being studied as an ADD ON to current antidepressant regimens - NO NEED TO STOP YOUR ANTIDEPRESSANT (which can be really scary to anyone on one).

1 · Reply

Crazydiamond311 Sep. 19 at 2:53 PM

$CMPS The future is bright for this little compound. Docoveries like this have the potential to spike revenue later on in the drug's life cycle and continue to print money. The original article was printed recently by Nature but this illustrates the biological mechanism occurring. Im curious what dose was required to show efficacy.

0 · Reply

KSR300 Sep. 19 at 2:21 PM

$CMPS Still got 2400 shares but lost 500 to cc on fridays push over $15 Going to sell November 18s for next leg up

0 · Reply

MurseOMoney Sep. 19 at 7:46 AM

$TRUFF Still unsure why this PHASE 3 study isn’t getting more heat 🌬️🔥 $CMPS $DFTX $ATAI $HELP

5 · Reply

MTT1992 Sep. 19 at 5:01 AM

$CMPS Pretty encouraged that we closed above $15 on low volume. No rush to profit taking, etc. Just hoping to continue the slow grind upward with small pops at NDA submission (although this event could be subject to ”sell the news”), approval, and DEA rescheduling. I still think a JNJ MMA is very possible as CMPS could get more expensive quickly. They’d probably need $5B minimum right now…

1 · Reply

Market Cap	2.10B
Revenue (ttm)	0.00
Net Income (ttm)	-287.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.60

Volume	3,574,300
Avg Vol	3,098,656
Day's Range	N/A - N/A
Shares Out	138.48M
Stochastic %K	75%
Beta	2.54
Analysts	Strong Sell
Price Target	$23.20